Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Trevi Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 53 | 55 | +2 |
| Shares | 48.8M | 48.7M | −139.4K (−0.3%) |
| Value | $116.7M | $106.1M | −$10.6M (−9.0%) |
New holders (6)
Institutions that held Trevi Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deutsche Bank AG | 25,070 | $54.7K | 0.00% |
| Jane Street Group, LLC | 24,600 | $53.6K | 0.00% |
| American Century Companies Inc | 21,427 | $46.7K | 0.00% |
| SG Americas Securities, LLC | 19,597 | $43.0K | 0.00% |
| Dimensional Fund Advisors LP | 18,382 | $40.1K | 0.00% |
| NBC Securities, Inc. | 2,000 | $4.00K | 0.00% |
Sold out (4)
Institutions that held Trevi Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Innovis Asset Management LLC | 43,232 | $103.3K |
| Susquehanna International Group, LLP | 11,571 | $27.7K |
| Zacks Investment Management | 10,000 | $23.9K |
| LPL Financial LLC | 10,000 | $23.9K |